BPG is committed to discovery and dissemination of knowledge
Randomized Controlled Trial
©The Author(s) 2025.
World J Clin Cases. Nov 6, 2025; 13(31): 109113
Published online Nov 6, 2025. doi: 10.12998/wjcc.v13.i31.109113
Table 3 Summary of symptoms reported, n (%)
Adverse event
Placebo (n = 40)
Physta® 50 mg (n = 36)
Physta® 100 mg (n = 36)
Total (n = 112)
Severity
Outcome
Related to product
Bloating2 (5.0)3 (8.3)4 (11.1)9 (8.0)MildResolvedNo
Headache1 (2.5)2 (5.6)2 (5.6)5 (4.5)MildResolvedNo
Breast tenderness0 (0.0)1 (2.8)2 (5.6)3 (2.7)MildResolvedNo
Flatulence1 (2.5)2 (5.6)2 (5.6)5 (4.5)MildResolvedNo
Abdominal discomfort1 (2.5)1 (2.8)2 (5.6)4 (3.6)MildResolvedNo
Total events5 (12.5)9 (25.0)12 (33.3)26 (23.2)---


Write to the Help Desk